| Large recurrent microdeletions associated with schizophrenia H Stefansson, D Rujescu, S Cichon, OPH Pietiläinen, A Ingason, ... nature 455 (7210), 232-236, 2008 | 2018 | 2008 |
| Mapping genomic loci implicates genes and synaptic biology in schizophrenia V Trubetskoy, AF Pardiñas, T Qi, G Panagiotaropoulou, S Awasthi, ... Nature 604 (7906), 502-508, 2022 | 1245 | 2022 |
| Meta-analysis of the association between the level of cannabis use and risk of psychosis A Marconi, M Di Forti, CM Lewis, RM Murray, E Vassos Schizophrenia bulletin 42 (5), 1262-1269, 2016 | 936 | 2016 |
| The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study M Di Forti, D Quattrone, TP Freeman, G Tripoli, C Gayer-Anderson, ... The Lancet Psychiatry 6 (5), 427-436, 2019 | 789 | 2019 |
| High-potency cannabis and the risk of psychosis M Di Forti, C Morgan, P Dazzan, C Pariante, V Mondelli, TR Marques, ... The British Journal of Psychiatry 195 (6), 488-491, 2009 | 714 | 2009 |
| Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study M Di Forti, A Marconi, E Carra, S Fraietta, A Trotta, M Bonomo, F Bianconi, ... The Lancet Psychiatry 2 (3), 233-238, 2015 | 662 | 2015 |
| Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users M Di Forti, H Sallis, F Allegri, A Trotta, L Ferraro, SA Stilo, A Marconi, ... Schizophrenia bulletin 40 (6), 1509-1517, 2014 | 570 | 2014 |
| Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes DM Ruderfer, S Ripke, A McQuillin, J Boocock, EA Stahl, JMW Pavlides, ... Cell 173 (7), 1705-1715. e16, 2018 | 519 | 2018 |
| Cannabis, the mind and society: the hash realities RM Murray, PD Morrison, C Henquet, MD Forti Nature Reviews Neuroscience 8 (11), 885-895, 2007 | 461 | 2007 |
| Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume V Mondelli, A Cattaneo, MB Murri, M Di Forti, R Handley, N Hepgul, ... The Journal of clinical psychiatry 72 (12), 20080, 2011 | 342 | 2011 |
| Gene-environment interplay between cannabis and psychosis C Henquet, M Di Forti, P Morrison, R Kuepper, RM Murray Schizophrenia bulletin 34 (6), 1111-1121, 2008 | 342 | 2008 |
| Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment V Mondelli, P Dazzan, N Hepgul, M Di Forti, M Aas, A D'Albenzio, ... Schizophrenia research 116 (2-3), 234-242, 2010 | 338 | 2010 |
| Traditional marijuana, high‐potency cannabis and synthetic cannabinoids: increasing risk for psychosis RM Murray, H Quigley, D Quattrone, A Englund, M Di Forti World Psychiatry 15 (3), 195-204, 2016 | 303 | 2016 |
| Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users M Di Forti, C Iyegbe, H Sallis, A Kolliakou, MA Falcone, A Paparelli, ... Biological psychiatry 72 (10), 811-816, 2012 | 300 | 2012 |
| Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses J Lally, O Ajnakina, M Di Forti, A Trotta, A Demjaha, A Kolliakou, ... Psychological medicine 46 (15), 3231-3240, 2016 | 290 | 2016 |
| Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? RM Murray, D Quattrone, S Natesan, J Van Os, M Nordentoft, O Howes, ... The British Journal of Psychiatry 209 (5), 361-365, 2016 | 289 | 2016 |
| Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis V Mondelli, S Ciufolini, M Belvederi Murri, S Bonaccorso, M Di Forti, ... Schizophrenia bulletin 41 (5), 1162-1170, 2015 | 287 | 2015 |
| Cannabis use in young people: the risk for schizophrenia P Casadio, C Fernandes, RM Murray, M Di Forti Neuroscience & Biobehavioral Reviews 35 (8), 1779-1787, 2011 | 254 | 2011 |
| Schizophrenia as a GSK-3 dysregulation disorder S Lovestone, R Killick, M Di Forti, R Murray Trends in neurosciences 30 (4), 142-149, 2007 | 244 | 2007 |
| The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability T Singh, JTR Walters, M Johnstone, D Curtis, J Suvisaari, M Torniainen, ... Nature genetics 49 (8), 1167-1173, 2017 | 232 | 2017 |
